Phaseline

Companies › VarmX

VarmX: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Hematology; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Reltodecacog alfa (VMX-C001)
Factor X (prothrombin complex) analog
F10Phase 3Blood Loss, SurgicalJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07288489Reltodecacog alfa (VMX-C001)Phase 3Blood Loss, SurgicalHematologyJan 2029

Targets

F10 (1)

Companies with the same targets

Roche Takeda Bayer Shaanxi Micot Pharmaceutical Technology

Companies built like this

Pharmanutra Vega Therapeutics MIBIO PTE. Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.